Schaper Benz & Wise Investment Counsel Inc. WI decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 1.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 112,494 shares of the company’s stock after selling 1,133 shares during the period. Johnson & Johnson comprises approximately 2.3% of Schaper Benz & Wise Investment Counsel Inc. WI’s holdings, making the stock its 11th largest holding. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in Johnson & Johnson were worth $15,718,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in JNJ. Arthur M. Cohen & Associates LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at about $5,875,000. Advisor Partners LLC boosted its position in Johnson & Johnson by 9.5% during the fourth quarter. Advisor Partners LLC now owns 68,801 shares of the company’s stock valued at $10,139,000 after purchasing an additional 5,949 shares in the last quarter. Nelson Roberts Investment Advisors LLC boosted its position in Johnson & Johnson by 172.5% during the fourth quarter. Nelson Roberts Investment Advisors LLC now owns 6,088 shares of the company’s stock valued at $851,000 after purchasing an additional 3,854 shares in the last quarter. Regent Investment Management LLC boosted its position in Johnson & Johnson by 0.8% during the fourth quarter. Regent Investment Management LLC now owns 47,171 shares of the company’s stock valued at $6,591,000 after purchasing an additional 385 shares in the last quarter. Finally, Waldron LP boosted its position in Johnson & Johnson by 25.1% during the fourth quarter. Waldron LP now owns 16,167 shares of the company’s stock valued at $2,258,000 after purchasing an additional 3,243 shares in the last quarter. Institutional investors and hedge funds own 67.23% of the company’s stock.
In other news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.22% of the company’s stock.
A number of brokerages recently weighed in on JNJ. Credit Suisse Group dropped their price objective on Johnson & Johnson from $154.00 to $151.00 and set an “outperform” rating on the stock in a research report on Friday. Wells Fargo reaffirmed an “outperform” rating and set a $150.00 price objective (down previously from $160.00) on shares of Johnson & Johnson in a research report on Wednesday, April 18th. Stifel Nicolaus dropped their price objective on Johnson & Johnson from $145.00 to $135.00 and set a “hold” rating on the stock in a research report on Wednesday, April 18th. Leerink Swann reaffirmed an “outperform” rating and set a $160.00 price objective (down previously from $175.00) on shares of Johnson & Johnson in a research report on Wednesday, April 18th. They noted that the move was a valuation call. Finally, Deutsche Bank reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, April 18th. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $142.83.
Johnson & Johnson stock opened at $126.66 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. Johnson & Johnson has a one year low of $121.54 and a one year high of $148.32. The stock has a market capitalization of $339,816.38, a price-to-earnings ratio of 17.35, a price-to-earnings-growth ratio of 1.96 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $2.00 by $0.06. Johnson & Johnson had a return on equity of 30.05% and a net margin of 1.58%. The company had revenue of $20.01 billion during the quarter, compared to analysts’ expectations of $19.50 billion. During the same period last year, the business posted $1.83 earnings per share. The firm’s revenue was up 12.6% compared to the same quarter last year. equities analysts predict that Johnson & Johnson will post 8.13 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Holdings Trimmed by Schaper Benz & Wise Investment Counsel Inc. WI” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/23/johnson-johnson-jnj-holdings-trimmed-by-schaper-benz-wise-investment-counsel-inc-wi.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.